Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $56.08 Average Price Target from Brokerages

by · The Cerbat Gem

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $56.0833.

CLDX has been the topic of several recent analyst reports. UBS Group raised their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Barclays upped their target price on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $42.00 price target on shares of Celldex Therapeutics in a research note on Monday, June 15th. Cantor Fitzgerald decreased their price target on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Finally, Canaccord Genuity Group lowered their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd.

Read Our Latest Stock Report on CLDX

Celldex Therapeutics Trading Up 1.1%

Shares of NASDAQ:CLDX opened at $40.38 on Thursday. The stock has a 50 day moving average of $37.72 and a 200 day moving average of $32.70. The company has a market cap of $3.17 billion, a PE ratio of -9.28 and a beta of 0.87. Celldex Therapeutics has a 12-month low of $21.33 and a 12-month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. Equities research analysts predict that Celldex Therapeutics will post -4.13 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares during the period. Millennium Management LLC lifted its holdings in shares of Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after buying an additional 306,330 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Celldex Therapeutics by 12.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after buying an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Celldex Therapeutics during the second quarter worth $347,000.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

Featured Stories